JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Probability of Financial Distress (%): 0.05% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:JSP JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP
80 GF Score
Price ฿1.75
GF Value ฿3.16
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is JSP Pharmaceutical Manufacturing (Thailand) PCL Probability of Financial Distress (%)?

JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP -1.69% 80 Probability of Financial Distress (%) is 0.05% as of Jul. 16, 2026. GuruFocus rates BKK:JSP with a GF Score™ of 80/100 and a GF Value™ of ฿3.16 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%) is 0.05%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


JSP Pharmaceutical Manufacturing (Thailand) PCL  (BKK:JSP) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


JSP Pharmaceutical Manufacturing (Thailand) PCL Probability of Financial Distress (%) Related Terms


BKK:JSP vs KHC, GIS: Probability of Financial Distress (%) Comparison

For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JSP Pharmaceutical Manufacturing (Thailand) PCL Probability of Financial Distress (%) vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%) falls into.


BKK:JSP
80GF Score
JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP
Probability of Financial Distress (%) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JSP Pharmaceutical Manufacturing (Thailand) PCL Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-7.61

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.05%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 0.05% mean?
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a Probability of Financial Distress (%) of 0.05% as of Jul. 16, 2026.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%) too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Probability of Financial Distress (%) is 0.05%. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%) compare to KHC and GIS?
JSP Pharmaceutical Manufacturing (Thailand) PCL's Probability of Financial Distress (%) of 0.05% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Consumer Packaged Goods company?
A good Probability of Financial Distress (%) depends on the Consumer Packaged Goods industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Probability of Financial Distress (%) is 0.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.16, compared to a current price of ฿1.75 — trading 44.6% below its estimated fair value. The current Probability of Financial Distress (%) is 0.05%. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current Probability of Financial Distress (%) is 0.05% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?

Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued. The current stock price of ฿1.75 is trading 44.6% below its estimated GF Value™ of ฿3.16. GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.

Key valuation signals for BKK:JSP:

  • Probability of Financial Distress (%): 0.05%
  • GF Value™: ฿3.16 vs. price of ฿1.75 (44.6% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description

Address No. 255, 257 Soi Sathupradit 58, Bang Pongphang, Yan Nawa, Bangkok, THA, 10120
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
80GF Score

Get the complete analysis for BKK:JSP

Probability of Financial Distress (%) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.75
Price
฿3.16
GF Value